November 2, 2017
1 pm to 2 pm EDT

Sponsored by

Webinar Description:

More than 50% of all cancer patients receive some sort of radiation therapy as part of their disease treatment plan. However, there remains a persistent lack of drug development with radiation combinations. In order to venture into clinical trials many drug developers want and need preclinical validation of their strategy. At MI Bioresearch we utilize the Small Animal Radiation Research Platform (SARRP; Xstrahl) to provide image-guided focal beam radiation in preclinical mouse models of oncology. In this webinar we will discuss the various models and methods that can be used to determine appropriate single agent radiation doses in syngeneic tumor models and discuss some of our data utilizing SARRP treatment in combination with check point inhibitors or conventional chemotherapy.

Learning Objectives:

• Basic radiobiology and role of radiation therapy in oncology treatment
• Comparison of broad field and focal radiation in preclinical cancer models
• Ability to combine radiation and chemotherapy in a human tumor xenograft model
• Sensitivity of murine syngeneic models to focal radiation
• Ability to combine radiation and a checkpoint inhibitor in a murine glioblastoma tumor model

Speakers:

Maryland Franklin, Ph.D.

Vice President, Scientific Development

MI Bioresearch

Dr. Maryland Franklin, Vice President, Scientific Development for MI Bioresearch, has over 20 years of experience with preclinical pharmacology models.  She has expertise in the design, execution, and analysis of in vivo pharmacology studies for oncology and was a key leader in bringing four drugs into Phase I clinical trials. Dr. Franklin joined MI in early 2014 and in her current role she is focused on strengthening MI’s in vivo animal model capabilities, overall oncology pharmacology and immuno-oncology services, and advancing internal drug discovery knowledge.

Sarah Krueger, Ph.D.

Scientist, Imaging Operations

MI Bioresearch

Dr. Sarah Krueger, Scientist, Imaging Operations, has 10 years of experience in preclinical cancer models with a background in cancer biology and radiobiology. She has intimate understanding of in vitro and in vivo pharmacology and radiobiology study execution and has worked on the development of small animal radiation models for over 7 years. Dr. Krueger joined MI in mid-2016 to facilitate the growth of the focal irradiation program and add depth to the imaging team, having previous expertise in MRI, PET, SPECT, CT and optical imaging techniques.